CIK 0001740279
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
IN8BIO, INC.
Sign in to watch- Ticker
- INAB
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 825462585
- Phone
- +1 646-600-6438
- Business address
- EMPIRE STATE BUILDING, 350 5TH AVENUE, SUITE 5330, NEW YORK, NY, 10118
- Former names
- Incysus Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-05-09 | McCall Patrick CHIEF FINANCIAL OFFICER | Grant or award · Employee Stock Option (right to buy) | +56,250 | 56,250 | ||
| 2026-02-04 | McCall Patrick CHIEF FINANCIAL OFFICER | Grant or award · Employee Stock Option (right to buy) | +75,000 | 75,000 | ||
| 2025-12-22 | McCall Patrick CHIEF FINANCIAL OFFICER | Grant or award | +7,247 | $1.38 | $10K | 9,482 |
| 2025-04-30 | McCall Patrick CHIEF FINANCIAL OFFICER | Option exercise | +15,000 | $0.18 | $3K | 67,071 |
| 2025-04-30 | McCall Patrick CHIEF FINANCIAL OFFICER | Option exercise · Series A Warrants (right to buy) | −15,000 | 0 | ||
| 2025-04-27 | McCall Patrick CHIEF FINANCIAL OFFICER | Returned to the company · Series A Warrants (right to buy) | −15,000 | 5,492 | ||
| 2025-04-27 | McCall Patrick CHIEF FINANCIAL OFFICER | Grant or award · Series A Warrants (right to buy) | +15,000 | 15,000 | ||
| 2025-04-27 | McCall Patrick CHIEF FINANCIAL OFFICER | Returned to the company · Series B Warrants (right to buy) | −20,492 | 0 | ||
| 2025-04-27 | McCall Patrick CHIEF FINANCIAL OFFICER | Grant or award · Series B Warrants (right to buy) | +20,492 | 20,492 | ||
| 2025-02-05 | McCall Patrick CHIEF FINANCIAL OFFICER | Grant or award · Employee Stock Option (right to buy) | +343,000 | 343,000 | ||
| 2024-12-19 | McCall Patrick CHIEF FINANCIAL OFFICER | Grant or award · Employee Stock Option (right to buy) | +290,085 | 290,085 | ||
| 2024-10-04 | McCall Patrick CHIEF FINANCIAL OFFICER | Grant or award | +25,316 | 52,071 | ||
| 2024-10-04 | McCall Patrick CHIEF FINANCIAL OFFICER | Returned to the company · Series A Warrants (right to buy) | −20,492 | 0 | ||
| 2024-10-04 | McCall Patrick CHIEF FINANCIAL OFFICER | Grant or award · Series A Warrants (right to buy) | +20,492 | 20,492 | ||
| 2024-10-04 | McCall Patrick CHIEF FINANCIAL OFFICER | Grant or award · Series C Warrants (right to buy) | +25,316 | 25,316 | ||
| 2024-09-04 | McCall Patrick CHIEF FINANCIAL OFFICER | Grant or award · Employee Stock Option (right to buy) | +250,000 | 250,000 | ||
| 2024-02-07 | McCall Patrick CHIEF FINANCIAL OFFICER | Grant or award · Employee Stock Option (right to buy) | +189,000 | 189,000 | ||
| 2023-12-13 | McCall Patrick Chief Financial Officer | Grant or award | +20,492 | 26,755 | ||
| 2023-12-13 | McCall Patrick Chief Financial Officer | Grant or award · Series A Warrants (right to buy) | +20,492 | 20,492 | ||
| 2023-12-13 | McCall Patrick Chief Financial Officer | Grant or award · Series B Warrants (right to buy) | +20,492 | 20,492 |
Page 1 of 2 · 27 trades